Can you believe ZILXI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
Zilxi is owned by Journey.
Zilxi contains Minocycline Hydrochloride.
Zilxi has a total of 8 drug patents out of which 0 drug patents have expired.
Zilxi was authorised for market use on 28 May, 2020.
Zilxi is available in aerosol, foam;topical dosage forms.
Zilxi can be used as treatment of inflammatory lesions of rosacea..
The generics of Zilxi are possible to be released after 01 October, 2030.
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of ZILXI before it's drug patent expiration?
More Information on Dosage
ZILXI family patents
